Innoviva Net Worth 2011-2025 | INVA
Interactive chart of historical net worth (market cap) for Innoviva (INVA) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Innoviva net worth as of November 12, 2025 is $1.38B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.380B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $934.625B | 44.96 |
| Johnson & Johnson (JNJ) | United States | $466.994B | 18.67 |
| AbbVie (ABBV) | United States | $397.962B | 23.83 |
| Roche Holding AG (RHHBY) | Switzerland | $289.080B | 0.00 |
| Novartis AG (NVS) | Switzerland | $275.671B | 14.61 |
| Merck (MRK) | United States | $225.740B | 10.51 |
| Novo Nordisk (NVO) | Denmark | $219.455B | 12.87 |
| Pfizer (PFE) | United States | $145.042B | 7.97 |
| Sanofi (SNY) | France | $126.925B | 12.19 |
| Bayer (BAYRY) | Germany | $31.104B | 5.86 |